For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative costs | 143,301 | 2,222,580 | 263,703 | 131,919 |
| Loss from operations | -143,301 | -2,222,580* | -263,703 | -131,919 |
| Interest earned on cash and investments held in trust account | 2,113,760 | 1,453,510 | 2,448,266 | 2,420,498 |
| Total other income | 2,113,760 | 1,453,510* | 2,448,266 | 2,420,498 |
| Net income | 1,970,459 | -769,070 | 2,184,563 | 2,288,579 |
| Basic EPS | 0.06 | -0.04 | 0.07 | - |
| Diluted EPS | 0.06 | -0.04 | 0.07 | - |
| Basic Average Shares | 23,000,000 | 19,016,438 | 23,000,000 | - |
| Diluted Average Shares | 23,000,000 | 19,016,438 | 23,000,000 | - |
Drugs Made In America Acquisition Corp. (DMAAR)
Drugs Made In America Acquisition Corp. (DMAAR)